Bayer CropScience Ltd
Bayer CropScience Q4 FY18 earnings call: Revenue & Margins
Q4 FY18 investor presentation: what the company reported on revenue, margins and projects.
Based on Bayer CropScience Ltd's Q4 FY18 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Sales for Bayer Global Q1 2018 were €9,138 million. EBITDA (before special items) for Bayer Global in Q1 2018: - Crop Science segment: €2,861 million, down 1.0% year-on-year (currency- and portfolio-adjusted) - Operating margin: - Crop Science segment declined by 6.5% in Q1 2018 year-on-year - Profit (PAT) for Financial Year 2017-18 (not quarter): - Profit Before Tax (PBT) decreased 9% over previous year; figures: PY 4,479 Mio INR, CY 4,038 Mio INR - No explicit margin outlook is stated in the presentation.
From Bayer CropScience Ltd's Q4 FY18 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Sales for Bayer Global Q1 2018 were €9,138 million.
- Year-on-year change (currency- and portfolio-adjusted):
- Consumer Health: -2.2%
- Crop Science: -1.0%
- Animal Health: +3.0%
- Pharmaceuticals: +2.9%
- EBITDA changes year-on-year:
- Pharmaceuticals: -5.8%
- Consumer Health: -20.2%
- Crop Science: -6.5%
- Animal Health: +3.0%
- Income overview for FY 2017-18:
- Total revenue decreased from INR 30,185 million (PY) to INR 27,878 million (CY).
- Exports contribution to revenue decreased from 14% to 9%.
- Domestic contribution increased from 81% to 86%.
- Outlook (Page 27 & 31):
- Positive outlook for 2018-19 based on good monsoon forecast.
- Expectation of positive commodity prices in 2018.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bayer CropScience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bayer CropScience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Bayer CropScience Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹162 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bayer CropScience Ltd's management said in earlier quarters
Frequently Asked Questions
What were Bayer CropScience Ltd Q4 FY18 results?
Sales for Bayer Global Q1 2018 were €9,138 million. EBITDA (before special items) for Bayer Global in Q1 2018: - Crop Science segment: €2,861 million, down 1.0% year-on-year (currency- and portfolio-adjusted) - Operating margin: - Crop Science segment declined by 6.5% in Q1 2018 year-on-year - Profit (PAT) for Financial Year 2017-18 (not quarter): - Profit Before Tax (PBT) decreased 9% over previous year; figures: PY 4,479 Mio INR, CY 4,038 Mio INR - No explicit margin outlook is stated in the presentation.
What is Bayer CropScience Ltd share price analysis?
Bayer CropScience Ltd currently shows a neutral. The stock trades at a P/E of 23.2 with a market cap of ₹16,986 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bayer CropScience Ltd planning capital expenditure?
The investor presentation does not provide explicit details on capex, capacity expansion, or specific new plant/project investments including amounts, status, or timelines.
Keep Bayer CropScience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.